Protein aggregation is a central pathological hallmark of virtually all neurodegenerative diseases, characterized by the abnormal accumulation of misfolded proteins into insoluble deposits within neurons and glia. This process represents a failure of cellular protein quality control systems and contributes directly to neuronal dysfunction and death through multiple mechanisms including proteotoxicity, sequestration of essential proteins, and disruption of cellular organelles.
The aggregation of proteins into ordered amyloid fibrils is now understood as a common pathological mechanism across diverse neurodegenerative conditions. Each major neurodegenerative disease is associated with specific aggregating proteins:
| Disease | Primary Aggregating Protein | Aggregate Form | Location |
|---|---|---|---|
| Alzheimer's disease | Amyloid-β (Aβ), Tau | Plaques, Neurofibrillary tangles | Extracellular, Intracellular |
| Parkinson's disease | α-Synuclein | Lewy bodies | Intracellular |
| ALS/FTD | TDP-43, FUS, SOD1 | Cytoplasmic inclusions | Intracellular |
| Huntington's disease | Mutant huntingtin | Nuclear inclusions | Intracellular |
| Prion diseases | Prion protein (PrP) | Amyloid plaques | Extracellular/Intracellular |
| PSP/CBS | 4R tau | Tufted astrocytes, astrocytic plaques | Intracellular |
Protein aggregation follows nucleation-dependent kinetics with distinct phases:
The rate-limiting nucleation step explains the long preclinical periods observed in neurodegenerative diseases.
Native proteins undergo partial unfolding to expose aggregation-prone regions:
Intermediate oligomers, rather than mature fibrils, may be the primary toxic species[1]:
Amyloid-β peptides (Aβ40, Aβ42) are produced through sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases:
Key aggregation determinants:
Tau normally functions as a microtubule-associated protein stabilizing axonal microtubules. In disease:
The 4R-tau isoforms show greater aggregation propensity in PSP and CBD, while 3R-tau dominates in Pick's disease.
α-Synuclein aggregation follows a prion-like propagation model:
The NAC (non-amyloid-β component) domain (residues 61-95) is essential for aggregation.
TDP-43 pathology involves:
Mutant huntingtin (mHTT) aggregation is the hallmark of Huntington's disease:
ALS-associated SOD1 mutations lead to toxic aggregation:
Cells respond to aggregation through multiple stress pathways:
Unfolded Protein Response (UPR)
Heat Shock Response
Aggregates specifically impair mitochondrial function:
Aggregate burden creates metabolic strain:
Current therapeutic strategies targeting protein aggregation:
| Approach | Example | Mechanism | Status |
|---|---|---|---|
| Antibody therapy | Lecanemab | Protofibril clearance | Approved |
| BACE inhibition | Elenbecestat | Reduce Aβ production | Terminated |
| γ-secretase modulation | Tg2576 approach | Modify Aβ ratio | Research |
| Aggregation inhibition | Rember | Fibril stabilization | Failed |
| Approach | Example | Mechanism | Status |
|---|---|---|---|
| Antibody therapy | Semorinemab | Tau clearance | Failed |
| Aggregation inhibitor | methylene blue derivatives | PHF stabilization | Phase III |
| O-GlcNAc promotion | Thiamet-G | Reduce phosphorylation | Preclinical |
| Kinase inhibitors | GSK3β inhibitors | Block tau phosphorylation | Research |
| Approach | Example | Mechanism | Status |
|---|---|---|---|
| Antibody therapy | Cinpanemab | Aggregate clearance | Phase II |
| Aggregation inhibitor | Anle138b | Oligomer modulation | Preclinical |
| Gene therapy | AAV-α-syn shRNA | Reduce expression | Preclinical |
| Cell replacement | Stem cell delivery | Neuronal replacement | Research |
Multi-target approaches may prove more effective:
| Model | Species | Pathology | Use |
|---|---|---|---|
| APP/PS1 | Mouse | Aβ plaques | Drug testing |
| 3xTg-AD | Mouse | Aβ + tau | Mechanism |
| α-synuclein Tg | Mouse | Lewy body-like | PD drug testing |
| SOD1 G93A | Mouse | Motor neuron loss | ALS studies |
| R6/2 | Mouse | Mutant HTT | HD studies |
Human biomarkers for clinical trials:
Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nature Medicine. 2004. ↩︎
Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017. ↩︎
Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nature Neuroscience. 2018. ↩︎